NCT07342478 2026-01-16ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLLNewave Pharmaceutical IncPhase 3 Not yet recruiting306 enrolled
NCT02337829 2026-01-08Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLLAcerta Pharma BVPhase 2 Completed48 enrolled 12 charts
NCT02966756 2025-12-24A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaAbbViePhase 2 Recruiting110 enrolled